Mucinex and Humibid will soon be the only long-acting guaifenesin products left standing

July 2007

Mucinex and Humibid will soon be the only long-acting guaifenesin products left standing.

The FDA already ordered all other SINGLE-ingredient long-acting guaifenesin products off the market in 2003 when Mucinex came out.

Now they are also targeting unapproved COMBO products that contain long-acting guaifenesin (Guaifenex, Crantex, etc).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Is Avandia really more dangerous than other medicines for diabetes, or is the news blowing the problem out of perspective
Obesity & Weight Loss Alli, (AL-eye) the new OTC orlistat for weight loss
Oral Health What do doctors mean when they write a prescription for "magic mouthwash"
Infectious Diseases patients asking about drug-resistant tuberculosis
Infectious Diseases artificial joints such as hips or knees are asking if they need antibiotics before going to the dentist
Respiratory & Allergy Mucinex and Humibid will soon be the only long-acting guaifenesin products left standing
Respiratory & Allergy Reps will be promoting Singulair (montelukast) for exercise-induced bronchospasm
Supplements More people will be taking vitamin D to try to prevent cancer
Women's Health the prospect of no periods with Lybrel, the first birth control pill approved for CONTINUOUS use
Billing issues stemming from the National Provider Identifier (NPI) number requirement are still getting sorted out
Lyme Disease New guidelines will influence the treatment of Lyme disease
Psychiatry Controversy is brewing, again, about generic substitution of antiepileptic drugs for seizures